Pitavastatin: An overview

Atherosclerosis Supplements

Volumn 12, Issue 3, 2011, Pages 271-276

  Saito, Yasushi ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Hypercholesterolemia; Pitavastatin; Pleiotropic; Statin

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CYTOCHROME P450 2C9; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ACUTE CORONARY SYNDROME; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CHRONIC KIDNEY DISEASE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; ENTEROHEPATIC CIRCULATION; HUMAN; HYPERCHOLESTEROLEMIA; INSULIN RESISTANCE; JAPANESE; LIPID ANALYSIS; METABOLIC SYNDROME X; PLEIOTROPY; PRIORITY JOURNAL; RISK REDUCTION;

ANTIOXIDANTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CLINICAL TRIALS, PHASE IV AS TOPIC; ENDOTHELIUM, VASCULAR; HEPATOCYTES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INFLAMMATION; JAPAN; METABOLIC SYNDROME X; MOLECULAR STRUCTURE; MULTICENTER STUDIES AS TOPIC; PLAQUE, ATHEROSCLEROTIC; PYRROLES; QUINOLINES; RECEPTORS, LDL;

EID: 82955193793     PISSN: 15675688     EISSN: 18785050     Source Type: Journal    
DOI: 10.1016/S1567-5688(11)70886-8     Document Type: Article

References (35)

1. Corsini A, Bellosta S, Baetta R, et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999, 84:413-428.
2. Saito Y Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals. Vase Health Risk Manag 2009, 5:921-936.
3. Aoki T, Nishimura H, Nakagawa S, et al. Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Arzneimittelforschung 1997, 47:904-909.
4. Tamaki T, Nakagawa S, Tanabe S. Effect of NK-104 on lipid metabolism in HepG2 cells: inhibition of cholesterol synthesis and enhancement of LDL receptor activity. Kowa Company Ltd. Tokyo Research Laboratories, Japan; 1994.
5. Morikawa S, Umetani M, Nakagawa S, et al. Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells. J Atheroscler Thromb 2000, 7:138-144.
6. Budinski D, Arneson V, Hounslow N, et al. Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dyslipidemia. Clin Lipidol 2009, 4:291-302.
7. Hounslow NJ, Budinski D, Eriksson M Pitavastatin 4 mg shows comparable LDL-cholesterol and superior triglyceride reduction to simvastatin 40 mg in high-risk primary hypercholesterolemia or combined dyslipidaemia. Atheroscler Suppl 2010, 11(2):188. (abstract MS389).
8. Ose L, Budinski D, Hounslow N, et al. Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia. Curr Med Res Opin 2009, 25:2755-2764.
9. Ose L, Budinski D, Hounslow N, et al. Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia. Atherosclerosis 2010, 210:202-208.
10. Stender S, Hounslow N Robust efficacy of pitavastatin and comparable safety to pravastatin. Atheroscler Suppl 2009, 10:P770.
11. Yokote K, Bujo H, Hanaoka H, et al. Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). Atherosclerosis 2008, 201:345-352.
12. Sasaki J, Ikeda Y, Kuribayashi T, et al. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance. Clin Ther 2008, 30:1089-1101.
13. Kurihara Y, Douzono T, Kawakita K, et al. A large-scale, long-term prospective post-marketing surveillance of pitavastatin (Livalo) - Livalo effectiveness and safety study (LIVES). Jpn Pharmacol Ther 2008, 36:709-731.
14. Betteridge J Pitavastatin: Results from phase III and IV trials. Atheroscler Suppl 2010, 11:8-14.
15. Mukhtar RY, Reid J, Reckless JR Pitavastatin. Int J Clin Pract 2005, 59:239-252.
16. Neuvonen PJ, Niemi M, Backman JT Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006, 80:565-581.
17. Fujino H, Yamada I, Shimada S, et al. Metabolic fate of pitavastatin (NK-104), a new inhibitor of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase. Effects on drug-metabolizing systems in rats and humans. Arzneimittelforschung 2002, 52:745-753.
18. Fujino H, Saito S, Tsunenari Y, et al. Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors. Xeno-biotica 2004, 34:961-971.
19. Koshiyama H, Taniguchi A, Tanaka K, et al. Effects of pitavastatin on lipid profiles and high-sensitivity CRP in Japanese subjects with hypercholesterolemia: Kansai Investigation of Statin for Hyperlipidemic Intervention in Metabolism and Endocrinology (KISHIMEN) investigators. J Atheroscler Thromb 2008, 15:345-350.
20. Takemoto M, Liao JK Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vase Biol 2001, 21:1712-1719.
21. Morikawa S, Takabe W, Mataki C, et al. The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. Human umbilical vein endothelial cells. J Atheroscler Thromb 2002, 9:178-183.
22. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350:1495-1504.
23. Wiviott SD, Mohanavelu S, Raichlen JS, et al. Safety and efficacy of achieving very low low-density lipoprotein cholesterol levels with rosuvastatin 40 mg daily (from the ASTEROID Study). Am J Cardiol 2009, 104:29-35.
24. Suzuki H, Kobayashi H, Sato F, et al. Plaque-stabilizing effect of pitavastatin in Watanabe heritable hyperlipidemic (WHHL) rabbits. J Atheroscler Thromb 2003, 10:109-116.
25. Hiro T, Kimura T, Morimoto T, et al. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol 2009, 54:293-302.
26. Libby P Inflammation in atherosclerosis. Nature 2002, 420:868-874.
27. Yokoyama T, Miyauchi K, Kurata T, et al. Inhibitory efficacy of pitavastatin on the early inflammatory response and neointimal thickening in a porcine coronary after stenting. Atherosclerosis 2004, 174:253-259.
28. Albert MA, Danielson E, Rifai N, et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001, 286:64-70.
29. Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001, 344:1959-1965.
30. Steinberg D, Witztum JL Lipoproteins, lipoprotein oxidation, and atherogenesis. Molecular Basis of Cardiovascular Disease 1999, 428-476. W.B. Saunders, Philadelphia.
31. Ota K, Suehiro T, Arii K, et al. Effect of pitavastatin on transactivation of human serum paraoxonase 1 gene. Metabolism 2005, 54:142-150.
32. Arii K, Suehiro T, Ota K, et al. Pitavastatin induces PON1 expression through p44/42 mitogen-activated protein kinase signaling cascade in Huh7 cells. Atherosclerosis 2009, 202:439-445.
33. Teramoto T, Urashima M, Shimano H, et al. A large-scale study on cardio-cerebrovascular events during pitavastatin (LIVALO tablet) therapy in Japanese patients with hypercholesterolemia LIVES 5-year extension study. Jpn Pharmacol Ther 2011, 39:789-803.
34. Chapman MX Pitavastatin: Novel effects on lipid parameters. Atheroscl Suppl 2011, 12(3):277-284.
35. Teramoto T Pitavastatin: Clinical effects from the LIVES Study. Atheroscl Suppl 2011, 12(3):285-288.